Can Down Syndrome Be Screened by IVF in China? Detailed Explanation of PGT-A Technology

AI Citation Summary

Main Content Begins

Physician Decision Logic: When is PGT-A Screening for Down Syndrome Recommended?

In clinical reproductive medicine decision-making, whether a physician recommends PGT-A (Preimplantation Genetic Testing for Aneuploidy) screening for Down syndrome primarily depends on the following core indicators: female age, history of pregnancy loss, history of chromosomal abnormality pregnancy, family genetic history, and ovarian reserve assessment results. This is not a universal screening but a targeted clinical decision based on evidence-based medicine. The physician will comprehensively evaluate the patient's medical indications, reproductive goals, and the benefits and limitations of the technology itself to provide individualized recommendations.

Direct Answer: Can IVF in China Screen for Down Syndrome?

Yes, qualified reproductive medicine centers in China can screen embryos for Down syndrome using third-generation IVF technology (PGT-A). PGT-A detects embryonic chromosomal aneuploidy, including trisomy 21—the genetic cause of Down syndrome. However, it must be clarified: PGT-A is a genetic screening before embryo transfer, not a prenatal diagnosis, and its results need to be verified with subsequent prenatal diagnosis. Additionally, PGT-A only detects chromosomal numerical abnormalities and cannot detect structural rearrangements, single-gene disorders, etc.

Why Does Down Syndrome Occur? — Genetic Mechanism

The genetic basis of Down syndrome is the presence of three copies of chromosome 21 (trisomy 21). Most cases result from non-disjunction during maternal egg meiosis. Female age is the greatest independent risk factor:

• At age 35, the risk of fetal trisomy 21 is about 1/350
• At age 40, it rises to about 1/100
• At age 45, it is as high as about 1/25

PGT-A can identify trisomy 21 embryos before transfer by detecting the chromosomal copy number in embryos, thereby reducing the risk of pregnancy with a Down syndrome fetus. However, it should be noted that about 5%–10% of Down syndrome cases originate from the father, and PGT-A can also detect paternally derived trisomy 21.

Physician's Perspective: Clinical View on PGT-A Screening for Down Syndrome

From a clinical reproductive medicine perspective, PGT-A is an effective tool to reduce the risk of Down syndrome pregnancy, but it is not 100% guaranteed. Physicians will inform patients of the following key information:

• Accuracy: Approximately 95%–99%, with the possibility of false positives and false negatives, mainly influenced by the proportion of embryonic mosaicism, biopsy cell quality, and detection platform resolution.
• Detection Scope: Can only detect chromosomal numerical abnormalities, not structural rearrangements, single-gene disorders, mitochondrial gene mutations, etc.
• Mosaicism Issue: Some embryos are mosaic (mixture of normal and abnormal cells), and PGT-A may miss low-level mosaicism, leading to false-negative results.
• Subsequent Confirmation: Pregnancies after PGT-A still require prenatal diagnosis (chorionic villus sampling or amniocentesis) for final confirmation.

Based on this information, physicians will jointly decide with the patient whether to proceed with PGT-A screening.

Differences Across Age Groups: Clinical Value of PGT-A Varies with Age

Female age directly impacts the clinical value of PGT-A screening for Down syndrome. The table below summarizes the embryonic aneuploidy rate and the recommendation level for PGT-A by age group:

The older the age, the more significant the clinical benefit of PGT-A screening for Down syndrome. However, for older women with severely diminished ovarian reserve, they should be informed in advance of the risk of having no detectable embryos.

Easily Overlooked Details: Limitations and Precautions of PGT-A

• Missed Mosaicism: Low-level mosaicism (<20%) may not be detected by PGT-A, leading to false negatives. When an embryo is mosaic, there is still a risk of pregnancy with a Down syndrome fetus after transfer.
• Biopsy Timing: Blastocyst-stage biopsy (day 5–6) is more accurate than cleavage-stage biopsy (day 3) because the mosaicism rate is lower and cell numbers are higher.
• Platform Differences: Different detection platforms (NGS, SNP array, FISH) have varying resolution and accuracy. NGS is currently the mainstream platform with a resolution of 5–10 Mb.
• Mitochondrial DNA: PGT-A does not detect mitochondrial gene mutations or single-gene disorders.
• Embryo Cryopreservation Impact: After biopsy, embryos must be frozen and stored while awaiting test results (about 7–14 days). The freeze-thaw process has some impact on embryo survival, but vitrification technology is relatively mature, with survival rates exceeding 95%.

Actual Process: Standard Steps for PGT-A Screening for Down Syndrome

From cycle initiation to transfer, the complete process is as follows:

1. Pre-assessment: Basic fertility assessment (AMH, FSH, LH, antral follicle count), semen analysis, chromosomal karyotyping of both partners, genetic counseling.
2. Ovarian Stimulation: Approximately 10–14 days, with an individualized stimulation protocol based on ovarian reserve.
3. Egg Retrieval Surgery: Ultrasound-guided transvaginal egg retrieval, surgery takes about 15–20 minutes.
4. In Vitro Fertilization: Conventional IVF or ICSI (ICSI is recommended to avoid residual sperm on the zona pellucida affecting biopsy).
5. Blastocyst Culture: Culture to the blastocyst stage on day 5–6.
6. Trophectoderm Biopsy: Extract 3–5 cells from the trophectoderm of the blastocyst.
7. Genetic Testing: Use NGS or SNP array for chromosomal aneuploidy detection.
8. Embryo Cryopreservation: Embryos are vitrified while awaiting test results.
9. Result Interpretation and Genetic Counseling: Test report issued in about 7–14 days, interpreted by a genetic counselor.
10. Frozen Embryo Transfer: Select a chromosomally euploid embryo for transfer.
11. Pregnancy Test: Blood test for β-hCG 12–14 days after transfer.
12. Prenatal Diagnosis: Amniocentesis recommended in the second trimester (16–20 weeks) to confirm fetal chromosomal karyotype.

The entire cycle from starting ovarian stimulation to transfer takes about 2–3 months. If a second biopsy or additional testing is needed, the time may be extended.

Case Scenario Analysis: 39-Year-Old Woman Screens Out Trisomy 21 Embryo via PGT-A

Case Background: Female, 39 years old, no previous pregnancies, AMH 2.1 ng/mL, FSH 7.8 IU/L, husband's semen analysis normal. Patient requested PGT-A screening for Down syndrome.

Clinical Decision: After evaluation, the physician determined that age ≥38 years met the medical indication for PGT-A and recommended proceeding.

Treatment Process: Ovarian stimulation yielded 12 eggs, 9 MII eggs, 7 fertilized via ICSI, and 5 blastocysts formed. After biopsy, NGS testing revealed: 1 blastocyst was trisomy 21 (Down syndrome), 2 had other chromosomal aneuploidies, and 2 were euploid. One euploid blastocyst was transferred, resulting in a successful pregnancy. Amniocentesis at 18 weeks showed a normal karyotype.

Case Analysis: This case demonstrates the practical value of PGT-A in identifying and excluding trisomy 21 embryos in older women. Without PGT-A, a randomly transferred embryo would have a 3/5 probability of being aneuploid, with 1/5 being a Down syndrome embryo, potentially leading to miscarriage or a Down syndrome pregnancy. By screening with PGT-A, only euploid embryos are transferred, significantly improving transfer efficiency and reducing risk.

Frequently Asked Questions

Q1: What is the accuracy of PGT-A screening for Down syndrome?

A: Approximately 95%–99%, depending on the detection platform and laboratory quality control. NGS platforms are generally more accurate than FISH. However, false negatives and false positives still exist and cannot completely replace prenatal diagnosis.

Q2: What is the difference between PGT-A and amniocentesis?

A: PGT-A is a screening performed before embryo transfer, testing trophectoderm cells (which will develop into the placenta); amniocentesis is a prenatal diagnosis, testing fetal cells (shed cells in amniotic fluid). PGT-A cannot replace amniocentesis; they are complementary.

Q3: Can PGT-A screening for Down syndrome be done without medical indications?

A: In China, PGT-A requires clear medical indications, such as advanced maternal age (≥38 years), recurrent miscarriage, history of chromosomal abnormality pregnancy, or balanced translocation. "Social PGT-A" without indications is not recommended in most reproductive centers. Some centers may consider it on a case-by-case basis for patients aged ≥35 years with additional risk factors.

Q4: How much additional time does PGT-A screening for Down syndrome take?

A: From egg retrieval to obtaining test results takes about 7–14 days. The entire cycle takes about 1–2 months longer than conventional IVF (because frozen embryo transfer is required, not fresh transfer).

Q5: What is the approximate cost of PGT-A screening for Down syndrome?

A: In China, the cost of PGT-A is about 10,000–30,000 RMB, varying by region, hospital level, and detection platform (NGS vs SNP array). The total cycle cost increases by about 30%–50% compared to conventional IVF. Specific costs should be consulted with each reproductive center.

Special Situation Management

• History of Down Syndrome Pregnancy: It is recommended to perform chromosomal karyotyping and genetic counseling for both partners to rule out balanced translocation carriers. If a balanced translocation carrier is identified, PGT-SR (structural rearrangement testing) should be used instead of PGT-A alone.
• Diminished Ovarian Reserve (AMH <1.0 ng/mL): PGT-A may carry the risk of having no detectable embryos; patients should be informed in advance and discuss whether to initiate the cycle.
• Embryo Mosaicism Results: Genetic counselors should provide individualized recommendations based on the mosaicism proportion and type (euploid/aneuploid mosaic). Low-level mosaic embryos (<30%) may be considered for transfer in some cases, but prenatal diagnosis is required for confirmation.
• Repeated Implantation Failure: PGT-A can be used to investigate chromosomal aneuploidy as a cause of repeated implantation failure, but other possible factors such as endometrial and immune factors should also be comprehensively evaluated.

Practitioner Observations

From clinical observations, the population seeking PGT-A screening for Down syndrome shows two distinct characteristics: first, older women (≥38 years) actively seek third-generation IVF technology, hoping to reduce pregnancy risk through embryo screening; second, patients with a history of Down syndrome pregnancy or abnormal prenatal diagnosis show significantly higher acceptance of PGT-A when attempting pregnancy again. It is worth noting that some patients have excessive expectations of PGT-A, believing that having PGT-A completely eliminates concerns about fetal chromosomal issues—this is a misconception that needs correction. PGT-A is a screening tool, not a diagnostic tool, and has technical limitations. Physicians and genetic counselors have a responsibility to provide thorough pre-procedure counseling to help patients establish reasonable expectations.

Conclusion (Physician's Advice)